EP11.01-008 Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System

Abstract

Hepatocyte growth factor receptor gene (MET) is one of the important therapeutic target genes in non-small cell lung cancer (NSCLC). Above all MET exon 14 skipping mutation (METex14skipping), which is caused by whole exon 14 deletion, base substitutions, insertions/deletions at the splice donor and acceptor sites, and Y1003 mutation, it is important in determining the decision for administration of selective MET inhibitor. One of the selective oral MET inhibitors, tepotinib, is only used in Japan when METex14skipping is detected by ArcherMET, a next generation sequencer.